

091-18784 *ju*

For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 -	and 9 Copies	Expires:

Estimated average burden hours per response: 2.00

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:
NYSE Arca, Inc.

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
Open-end Management Investment Company


**SEC
Mail Processing
Section**

3. Class of New Derivative Securities Product:
Investment Company Units

**JUN 25 2015
Washington DC
404**

4. Name of Underlying Instrument:
S&P Biotech Select Industry Total Return Index

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:
Narrow-Based



6. Ticker Symbol(s) of New Derivative Securities Product:
LABD

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:
NYSE, NYSE MKT, NASDAQ

8. Settlement Methodology of New Derivative Securities Product:
Regular way trades settle on T+3/Book entry only held in DTC.

9. Position Limits of New Derivative Securities Product (if applicable):
Not applicable.

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:
Martha Redding

Title:
Senior Counsel and Assistant Corporate Secretary

Telephone Number:
(212) 656-2938

Manual Signature of Official Responsible for Form:
Martha Redding

Date:
June 23, 2015

SEC 2449 (1/99)

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability	JUN 25 2015

**RECEIVED
JUN 25 AM 1:42
SEC / INT**



Martha Redding
Senior Counsel
Assistant Corporate Secretary

New York Stock Exchange
11 Wall Street
New York, NY 10005
T + 1 212 656 2938
F + 1 212 656 8101
Martha.Redding@theice.com

Via Overnight Mail

June 23, 2015

Ms. Gail Jackson
US Securities and Exchange Commission
Division of Trading and Markets
Station Place – Building I
100 F Street, N.E. – Room 6628
Washington, DC 20549

SEC
Mail Processing
Section
JUN 25 2015
Washington DC
404

Re: 19b-4(e) – Transmittal


Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

Direxion Daily S&P Biotech Bear 3X Shares (LABD)

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,


Enclosures

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	JUN 25 2015

RECEIVED
JUN 25 AM 11:42
SEC